All the
latest

May 24, 2023

Ultragenyx Issues 2022 Environmental, Social and Governance (ESG) Report

Rare disease biotech company continues to enhance its leadership on corporate responsibility NOVATO, Calif., May 24, 2023 -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultrarare diseases,

Read more
May 19, 2023

Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit

NOVATO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's

Read more